AstraZeneca stock heads into the open after a 0.43% slide
Published on 09/14/2026 at 06:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock closed at 11,708.0 GBX on the London Stock Exchange on September 11, 2026, down 0.43% from the prior session. The move left the shares weaker than the broader FTSE 100 index on the same day.
September 11, 2026 in numbers
AstraZeneca PLC (ISIN GB0009895292) recorded an intraday high of 11,960.0 GBX and a low matching the close at 11,708.0 GBX on September 11, 2026, with trading volume around 1.47 million shares according to price history data. On a reference basis, the FTSE 100 index also declined on September 11, 2026, but AstraZeneca’s 0.43% drop meant the stock lagged the home benchmark. Per Nasdaq data from MarketWatch, the company’s New York listed shares ended the same date at 160.17 USD, a 0.33% gain, highlighting a divergence between the London line and the US listing.
Session sentiment was constrained by research news, as a phase 3 trial of a combined treatment for breast cancer did not meet its primary endpoint, a setback reported by Zonebourse on September 11, 2026. The same report noted that, over the five trading days up to September 11, 2026, AstraZeneca shares fell 2.48% and were down 15.10% since the start of 2026, underscoring that the latest decline extended an existing negative trend.
Today’s drivers for AstraZeneca stock
Looking at the immediate calendar, AstraZeneca’s next scheduled earnings release is indicated for October 30, 2026, in an overview by Yahoo Finance, so no company-specific results are due today. However, investors remain attentive to further communication around oncology and cardiovascular pipelines after the recent breast cancer trial miss highlighted by Zonebourse. Broader market conditions from the United Kingdom, including movements in the FTSE 100 and sector peers, are likely to frame trading in AstraZeneca stock today ahead of the open.
